Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Pediatr Blood Cancer. 2017 Sep 17;65(2):10.1002/pbc.26825. doi: 10.1002/pbc.26825

Figure 2.

Figure 2

Tumor models where M6620 statistically significantly increased the efficacy of cisplatin; NB-EBc1 (neuroblastoma), BT-29(CNS rhabdoid), KT-5 (Wilms tumor), and OS-9 (osteosarcoma). Individual tumor volume graphs are shown for Control, cisplatin, M6620 and combination treatment groups. Kaplan Meier Event-Free survival plots are shown in the right panels. Control (black solid line), cisplatin orange broken line), M6620 (blue broken line) or combination (purple broken line) treated groups.